Provided by Tiger Trade Technology Pte. Ltd.

Co-Diagnostics, Inc.

2.59
-0.0600-2.26%
Post-market: 2.41-0.1801-6.95%19:59 EDT
Volume:56.75M
Turnover:196.41M
Market Cap:5.43M
PE:-0.09
High:3.95
Open:3.86
Low:2.47
Close:2.65
52wk High:46.50
52wk Low:2.05
Shares:2.10M
Float Shares:1.99M
Volume Ratio:169.61
T/O Rate:2849.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-29.0077
EPS(LYR):-37.2229
ROE:-62.12%
ROA:-37.92%
PB:0.14
PE(LYR):-0.07

Loading ...

Co-Diagnostics Inc - Reverse Stock Split Effective January 2, 2026

THOMSON REUTERS
·
Dec 30, 2025

Co-Diagnostics Inc - Filed Amendment to Effect Reverse Stock Split of Its Common Stock at a Ratio of 1-for-30 Shares

THOMSON REUTERS
·
Dec 30, 2025

Co-Diagnostics Inc. Granted Australian Patent for Point-of-Care PCR Testing Platform

Reuters
·
Dec 29, 2025

CoSara Diagnostics Invited to Advanced TB Diagnostics Workshop in India

Reuters
·
Dec 18, 2025

Co-Diagnostics Confirms Flu Test Effectiveness Against Emerging H3N2 Mutation

Reuters
·
Dec 17, 2025

Co-Diagnostics Unveils Portable Cloud-Connected PCR Platform at Boston Conference

Reuters
·
Dec 09, 2025

CoSara Diagnostics to Showcase New PCR Tests at VIROCON 2025

Reuters
·
Dec 09, 2025

Co-Diagnostics Inc. held shareholder meeting on reverse stock split proposal

Reuters
·
Dec 06, 2025

Co-Diagnostics Initiated at Buy by Maxim Group

Dow Jones
·
Nov 26, 2025

Co-Diagnostics Inc : Maxim Group Initiates Coverage With Buy Rating; Target Price $1.5

THOMSON REUTERS
·
Nov 26, 2025

Analysts Offer Insights on Healthcare Companies: Co-Diagnostics (CODX), Stevanato Group (STVN) and Alpha Cognition Inc (ACOG)

TIPRANKS
·
Nov 24, 2025

Co-Diagnostics Addresses Tuberculosis Test Adoption at The Union World Conference on Lung Health

Reuters
·
Nov 20, 2025

Co-Diagnostics Initiates Clinical Evaluations For Upper Respiratory Multiplex Point-Of-Care Test On Co-Dx™ Pcr Platform To Support Submission To The U.S. FDA

Reuters
·
Nov 20, 2025

Co-Diagnostics Launches Clinical Trials for Multiplex PCR Respiratory Test

Reuters
·
Nov 18, 2025

Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™ Pcr Platform to Support Submission to the U.S. FDA

THOMSON REUTERS
·
Nov 18, 2025

Co-Diagnostics Raises $3.8 Million in Registered Direct Offering

Reuters
·
Nov 14, 2025

Co-Diagnostics reports Q3 net loss of $5.9 million on $11.4 million in cash and securities

Reuters
·
Nov 14, 2025

Co-Diagnostics Launches Joint Venture with Arabian Eagle Manufacturing for MENA Expansion

Reuters
·
Nov 14, 2025

BRIEF-Co-Diagnostics Q3 Revenue USD 100 Thousand

Reuters
·
Nov 14, 2025

Co-Diagnostics Q3 Adjusted Ebitda USD -6.3 Million

THOMSON REUTERS
·
Nov 14, 2025